News | February 27, 2009

Mercy Hospital First in Miami-Dade to Implant Insertable Cardiac Monitor

February 27, 2009 - Dr. Alberto Interian Jr., medical director of the Mercy Hospital Arrhythmia Syncope Center, is the first doctor in Miami-Dade County, FL to implant an innovative cardiac monitoring device for patients with irregular heart rhythms (arrhythmias), or recurrent, unexplained fainting (syncope).
The Medtronic Reveal XT Insertable Cardiac Monitor (ICM) device monitors patients 24 hours a day, every day for up to three years, recording important cardiac rhythm trend data that may allow a physician to confirm or rule out an abnormal heart rhythm more definitively than other tests.

“Cardiac arrhythmias are unpredictable,” said Dr. Interian. “The Reveal XT device gives me a long-term monitoring option that further assists me in making a diagnosis and determining the appropriate treatment for my patients.”

Physicians may choose the Reveal XT monitor for their patients with suspected arrhythmias in difficult-to-diagnose patients for whom long-term cardiac rhythm trending data may aid in a more informed diagnosis; or in syncope patients with known or suspected atrial fibrillation (AF), where the heart quivers and cannot effectively pump blood to the body’s organs.

The ICMs are also an option for physicians seeking to detect the presence of atrial arrhythmias (irregular heart rhythms in the upper chambers, also known as AT), including asymptomatic episodes, or to monitor the amount of time a patient is in AT/AF to assess whether medical treatment is necessary or should be adjusted.

Placed just under the skin of the chest area using local anesthesia during a simple outpatient procedure, the device weighs just 15 grams and is approximately the size of a jump drive. Unlike a pacemaker or implantable cardioverter-defibrillator, there are no leads or tiny wires that extend from the device into the heart’s chambers. To store an electrocardiogram (ECG), a patient places a hand-held, pager-sized assistant over the device and presses a button. The physician can then analyze the stored information, transmitted via the Medtronic CareLink Network or during an in-office patient visit, and determines whether the episode was caused by an abnormal heart rhythm.

For more information: www.mercymiami.org

Related Content

A view of the EPD Solutions catheter ablation system image guidance. It displays the catheter within a pre-acquired 3D segmented CT image. The D700 system provides a real-time lesion assessment tool that predicts transmurality and permanency of lesions, pre- and immediately post-ablation.

A view of the EPD Solutions catheter ablation system image guidance. It displays the catheter within a pre-acquired 3D segmented CT image. The D700 system provides a real-time lesion assessment tool that predicts transmurality and permanency of lesions, pre- and immediately post-ablation.

News | EP Lab | June 05, 2018
June 5, 2018 — Philips Healthcare has signed an agreement to acquire EPD Solutions, a provider of image-guidance in c
A recent study shows the Baylis NRG radiofrequency (RF) Transseptal puncture catheter has a lower incidence of embolism in EP cases.
News | EP Lab | May 21, 2018
May 21, 2018 — A recent study published in Heart and Vessels has found that the use of the Baylis Medical NR
Myocarditis is an Under-recognized Etiology of Symptomatic Premature Ventricular Arrhythmia (PVCs). #HRS #HRS2018
News | EP Lab | May 18, 2018
May 18, 2018 — A significant number of patients with symptomatic premature ventricular contractions (PVCs) have under
Novel Antibiotics Can Help Lower EP Device Infection Rates. Pictured here is an ICD. Implantation of pacemakers, ICDs and the related cardiac leads opens patients to infection risk.

Implantation of pacemakers, ICDs and the related cardiac leads opens patients to infection risk.

News | EP Lab | May 17, 2018
May 10, 2018 – A new study is the first to test the clinical effectiveness of incremental peri-operative antibiotics
The Apple Watch Series 2, Samsung Galaxy Gear S3 and the Fitbit Charge 2 were all able to properly diagnose the very rapid heart beats involved in  paroxysmal supraventricular tachycardia (PSVT). #HRS2018

The Apple Watch Series 2, Samsung Galaxy Gear S3 and the Fitbit Charge 2 were all able to properly diagnose the very rapid heart beats involved in  paroxysmal supraventricular tachycardia (PSVT).  

News | EP Lab | May 16, 2018
May 16, 2018 — A new study is the first to validate the accuracy of wrist-worn wearable devices in measuring induced
LivaNova Completes Sale of Cardiac Rhythm Management (CRM - electrophysiology) Business to MicroPort Scientific
News | EP Lab | April 30, 2018
April 30, 2018 — LivaNova announced it completed the sale of its cardiac rhythm management (CRM) business to MicroPor
LivaNova Enters Binding Letter of Intent to Sell Cardiac Rhythm Management Business
News | EP Lab | January 26, 2018
January 26, 2018 — LivaNova PLC and MicroPort Scientific Corp.
Societies Detail Treatment for Patients With Ventricular Arrhythmias
News | EP Lab | October 30, 2017
The American College of Cardiology, along with the American Heart Association and the Heart Rhythm Society, published...
Baylis Medical and Siemens Co-Sponsor Transseptal Access Training Course
News | EP Lab | October 18, 2017
Baylis Medical Co. Inc. and Siemens Healthineers are co-sponsoring a first-of-its kind training program aimed at...
Spectranetics Initiates Class I Recall for Bridge Occlusion Balloon Catheter
News | EP Lab | September 27, 2017
Spectranetics is recalling its Bridge Occlusion Balloon Catheter due to the possibility of a blocked guidewire lumen in...
Overlay Init